Keyphrases
Turkey
100%
Clinical Trials
100%
Clinical Application
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Chimeric Antigen Receptor T-cell Therapy
75%
Tumor
50%
Progressive Disease
50%
Production Data
50%
Acute Lymphoblastic Leukemia
50%
Non-Hodgkin Lymphoma
50%
CD19+
50%
Partial Response
50%
Response Rate
25%
Effective Treatment
25%
Toxicity Profile
25%
Treatment Options
25%
Clinical Outcomes
25%
Clinical Data
25%
Cell Infusion
25%
Quality Control
25%
Academic Production
25%
Adoptive Cell Therapy
25%
Economical Treatment
25%
Encephalopathy Syndrome
25%
Heavily Pretreated
25%
Rate Profile
25%
Leukemia Patients
25%
B-cell Malignancies
25%
Quality Criteria
25%
Overall Response Rate
25%
Refractory Patients
25%
Safe Treatment
25%
Commercial Products
25%
Lymphoma Patients
25%
Pancytopenia
25%
Pilot Randomized Controlled Trial
25%
Cytokine Release Syndrome
25%
Medicine and Dentistry
Chimeric Antigen Receptor
100%
Infusion
50%
Neoplasm
50%
Acute Lymphoblastic Leukemia
50%
Non-Hodgkin Lymphoma
50%
Chimeric Antigen Receptor T-Cell Immunotherapy
50%
Progressive Disease
50%
Brain Disease
25%
Cytokine Release Syndrome
25%
Pancytopenia
25%
B Cell
25%
Chimeric Antigen Receptor T-Cell
25%
T Cell
25%
Cell Therapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chimeric Antigen Receptor
100%
Nonhodgkin Lymphoma
28%
Disease
28%
Neoplasm
28%
Acute Lymphoblastic Leukemia
28%
Syndrome
14%
Brain Disease
14%
Cytokine Release Syndrome
14%
Pancytopenia
14%